GW Pharmaceuticals PLC Sponsored ADR
(NASDAQ : GWPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading GWPH News...
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
1.13%16.5910.2%$228.70m
SHPGShire PLC Sponsored ADR
0.13%180.890.3%$189.02m
PRGOPerrigo Co. Plc
-0.37%84.364.3%$142.10m
MNKMallinckrodt Plc
0.91%54.6011.1%$110.66m
MDCOMedicines Company
-1.67%52.4419.0%$99.70m
ENDPEndo International Plc
0.52%13.269.0%$98.67m
PRXLPAREXEL International Corporation
0.05%65.837.5%$84.18m
UTHRUnited Therapeutics Corporation
-9.43%152.0913.5%$77.75m
JAZZJazz Pharmaceuticals Plc
-0.85%134.782.3%$70.77m
ICPTIntercept Pharmaceuticals, Inc.
-0.91%124.3121.9%$66.61m
SAGESAGE Therapeutics, Inc.
-1.18%63.3112.1%$48.60m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-2.74%125.8810.9%$47.56m
SGYPSynergy Pharmaceuticals, Inc.
-2.32%5.7016.1%$41.64m
HZNPHorizon Pharma plc
0.67%17.3111.1%$40.07m
PTLAPortola Pharmaceuticals, Inc.
-1.93%32.038.8%$39.81m

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development, and Pipeline Research & Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.